The EORTC CLTF 20-21 Meeting took place from 14-16 October, 2021, as both a live meeting in Marseille, France, and as a virtual event. This meeting covered the latest updates in cutaneous lymphoma.

Related content: Managing CD30+ CTCL: UK patient experience

Managing CD30+ CTCL - UK Patient Experience
View all videos

EORTC CLTF 2021

The European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 20-21 Meeting
14–16 October 2021 | Hybrid: Marseille, France & Virtual
VJHemOncVJHemOnc@VJHemOnc·
6h

💥New: Phase III INDEPENDENCE trial of luspatercept in patients with TD #Myelofibrosis on JAKi therapy💥

Ruben Mesa (@mpdrc) of @UTHealthSAMDA talks on the rationale & design of the currently enrolling study: http://ow.ly/4I5F50HzL3b

#ASH21 #HemOnc #MPNsm #TrialUpdate #CTSM

Reply on Twitter 1485895222689153026Retweet on Twitter 14858952226891530261Like on Twitter 1485895222689153026View Tweet 1485895222689153026
Retweet on TwitterVJHemOnc Retweeted
chanyooncheahChan Cheah@chanyooncheah·
7h

The latest Lymphoma: Today! https://paper.li/chanyooncheah/1505376789?edition_id=e9b006b0-7db6-11ec-aab8-fa163ed80008 Thanks to @VJHemOnc @smbenlazar @lymphomahub #lymphoma #lymsm

Reply on Twitter 1485888964368400385Retweet on Twitter 14858889643684003852Like on Twitter 14858889643684003854View Tweet 1485888964368400385
VJHemOncVJHemOnc@VJHemOnc·
7h

The 2022 4th European CAR T-Cell Meeting is fast approaching – are you ready to be a part of this great experience 🤩? Stay tuned with us @VJHemOnc for regular updates!

@TheEBMT @EHA_Hematology #CART22 #CARTtherapy #ImmunoOnc #HemOnc #tcellrx #MMsm #LYMsm #AMLsm #CARTcell

Reply on Twitter 1485885381585379328Retweet on Twitter 14858853815853793281Like on Twitter 14858853815853793282View Tweet 1485885381585379328
Retweet on TwitterVJHemOnc Retweeted
doctorpemmNaveen Pemmaraju, MD@doctorpemm·
23 Jan

Today is #BPDCNDay {1-23, #CD123}. Please help me raise awareness for research&novel therapeutics for our patients,families&caregivers facing #BPDCN. I have dedicated my life & career for this cause&will always keep going for you! @lane_andy @JoeKhouryMD @sanamloghavi @tmprowell

4
Reply on Twitter 1485386287490252802Retweet on Twitter 148538628749025280222Like on Twitter 148538628749025280287View Tweet 1485386287490252802
Retweet on TwitterVJHemOnc Retweeted
VincentRKVincent Rajkumar@VincentRK·
22h

A study of 61,437 people with myeloma: 3783 from @MayoClinic and 57,654 from SEER Registry shows remarkable improvement in overall survival of myeloma over time. @MoritzBinderMD @LeukemiaJnl @MayoCancerCare @MayoMyeloma https://www.nature.com/articles/s41375-021-01453-5

Reply on Twitter 1485653875881357314Retweet on Twitter 148565387588135731411Like on Twitter 148565387588135731427View Tweet 1485653875881357314
Load More...

EORTC CLTF 2021

The European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 20-21 Meeting
14–16 October 2021 | Hybrid: Marseille, France & Virtual

The EORTC CLTF 20-21 Meeting took place from 14-16 October, 2021, as both a live meeting in Marseille, France, and as a virtual event. This meeting covered the latest updates in cutaneous lymphoma.

Related content: Managing CD30+ CTCL: UK patient experience

Managing CD30+ CTCL - UK Patient Experience
View all videos
VJHemOncVJHemOnc@VJHemOnc·
6h

💥New: Phase III INDEPENDENCE trial of luspatercept in patients with TD #Myelofibrosis on JAKi therapy💥

Ruben Mesa (@mpdrc) of @UTHealthSAMDA talks on the rationale & design of the currently enrolling study: http://ow.ly/4I5F50HzL3b

#ASH21 #HemOnc #MPNsm #TrialUpdate #CTSM

Reply on Twitter 1485895222689153026Retweet on Twitter 14858952226891530261Like on Twitter 1485895222689153026View Tweet 1485895222689153026
Retweet on TwitterVJHemOnc Retweeted
chanyooncheahChan Cheah@chanyooncheah·
7h

The latest Lymphoma: Today! https://paper.li/chanyooncheah/1505376789?edition_id=e9b006b0-7db6-11ec-aab8-fa163ed80008 Thanks to @VJHemOnc @smbenlazar @lymphomahub #lymphoma #lymsm

Reply on Twitter 1485888964368400385Retweet on Twitter 14858889643684003852Like on Twitter 14858889643684003854View Tweet 1485888964368400385
VJHemOncVJHemOnc@VJHemOnc·
7h

The 2022 4th European CAR T-Cell Meeting is fast approaching – are you ready to be a part of this great experience 🤩? Stay tuned with us @VJHemOnc for regular updates!

@TheEBMT @EHA_Hematology #CART22 #CARTtherapy #ImmunoOnc #HemOnc #tcellrx #MMsm #LYMsm #AMLsm #CARTcell

Reply on Twitter 1485885381585379328Retweet on Twitter 14858853815853793281Like on Twitter 14858853815853793282View Tweet 1485885381585379328
Retweet on TwitterVJHemOnc Retweeted
doctorpemmNaveen Pemmaraju, MD@doctorpemm·
23 Jan

Today is #BPDCNDay {1-23, #CD123}. Please help me raise awareness for research&novel therapeutics for our patients,families&caregivers facing #BPDCN. I have dedicated my life & career for this cause&will always keep going for you! @lane_andy @JoeKhouryMD @sanamloghavi @tmprowell

4
Reply on Twitter 1485386287490252802Retweet on Twitter 148538628749025280222Like on Twitter 148538628749025280287View Tweet 1485386287490252802
Retweet on TwitterVJHemOnc Retweeted
VincentRKVincent Rajkumar@VincentRK·
22h

A study of 61,437 people with myeloma: 3783 from @MayoClinic and 57,654 from SEER Registry shows remarkable improvement in overall survival of myeloma over time. @MoritzBinderMD @LeukemiaJnl @MayoCancerCare @MayoMyeloma https://www.nature.com/articles/s41375-021-01453-5

Reply on Twitter 1485653875881357314Retweet on Twitter 148565387588135731411Like on Twitter 148565387588135731427View Tweet 1485653875881357314
Load More...

Latest Videos

View all
1:23
Pegylated liposomal doxorubicin as maintenance in mycosis fungoides
Pablo Ortiz Romero • 14 Oct 2021
0:32
Patient selection for CTCL
Amra Osmancevic • 15 Oct 2021
0:57
Novel targets in the treatment of CTCL
Jan P. Nicolay • 15 Oct 2021
1:10
The role of transplant in CTCL
Julia Jane Scarisbrick • 15 Oct 2021

Brentuximab vedotin

View all
1:47
Brentuximab vedotin for CTCL
Christoph Blazejak • 15 Oct 2021
0:46
ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL
Julia Jane Scarisbrick • 15 Oct 2021

Mogamulizumab

View all
0:41
Recent advances in understanding and managing CTCL
Robert Knobler • 15 Oct 2021
0:38
Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab
Pablo Ortiz Romero • 14 Oct 2021

Diagnostics

View all
0:48
Integrating data to improve CBCL diagnosis
Jean-Philippe Merlio • 14 Oct 2021
4:24
Risk stratification of patients with PTCL using molecular profiling
Marta Rodriguez-Moreno • 11 Oct 2021
1:15
Improving TTD and supporting patient advocacy in CTCL
Chalid Assaf • 14 Oct 2021
1:05
The diagnostic work-up of CBCL in Sweden
Amra Osmancevic • 15 Oct 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals